ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability
Scheffler, Matthias (Center for Integrated Oncology Köln Bonn (Cologne, Alemanya))
Schultheis, Anne M. (Center for Integrated Oncology Köln Bonn (Cologne, Alemanya))
Teixidó, Cristina (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya))
Michels, Sebastian (Center for Integrated Oncology Köln Bonn (Cologne, Alemanya))
Morales Espinosa, Daniela (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Viteri, Santiago (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya))
Hartmann, Wolfgang (University Hospital of Münster (Alemanya))
Merkelbach Bruse, Sabine (Center for Integrated Oncology Köln Bonn (Cologne, Alemanya))
Fischer, Rieke (Center for Integrated Oncology Köln Bonn (Cologne, Alemanya))
Schildhaus, Hans Ulrich (University Medical Center of Göttingen (Alemanya))
Fassunke, Jana (Center for Integrated Oncology Köln Bonn (Cologne, Alemanya))
Sebastian, Martin (University Hospital of Frankfurt (Alemanya))
Serke, Monika (Lung Clinic Hemer (Alemanya))
Kaminsky, Britta (Bethanien Hospital (Solingen, Alemanya))
Randerath, Winfried (Bethanien Hospital (Solingen, Alemanya))
Gerigk, Ulrich (Malteser Hospital Seliger Gerhard Bonn/Rhein-Sieg (Alemanya))
Ko, Yon-Dschun (Johanniter Hospital (Bonn, Alemanya))
Krüger, Stefan (Florence-Nightingale Hospital (Düsseldorf, Alemanya))
Schnell, Roland
Rothe, Achim
Kropf Sanchen, Cornelia (University Hospital of Ulm (Alemanya))
Heukamp, Lukas (Center for Integrated Oncology Köln Bonn (Cologne, Alemanya))
Rosell, Rafael (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya))
Büttner, Reinhard (Center for Integrated Oncology Köln Bonn (Cologne, Alemanya))
Wolf, Jürgen (Center for Integrated Oncology Köln Bonn (Cologne, Alemanya))

Fecha:	2015
Resumen:	BACKGROUND: While recent data show that crizotinib is highly effective in patients with ROS1 rearrangement, few data is available about the prognostic impact, the predictive value for different treatments, and the genetic heterogeneity of ROS1-positive patients. PATIENTS AND METHODS:1137 patients with adenocarcinoma of the lung were analyzed regarding their ROS1 status. In positive cases, next-generation sequencing (NGS) was performed. Clinical characteristics, treatments and outcome of these patients were assessed. Overall survival (OS) was compared with genetically defined subgroups of ROS1-negative patients. RESULTS: 19 patients of 1035 evaluable (1. 8%) had OS1-rearrangement. The median OS has not been reached. Stage IV patients with ROS1-rearrangement had the best OS of all subgroups (36. 7 months, p < 0. 001). 9 of 14 (64. 2%) patients had at least one response to chemotherapy. Estimated mean OS for patients receiving chemotherapy and crizotinib was 5. 3 years. Ten patients with ROS1-rearrangement (52. 6%) harbored additional aberrations. CONCLUSION: ROS1-rearangement is not only a predictive marker for response to crizotinib, but also seems to be the one of the best prognostic molecular markers in NSCLC reported so far. In stage IV patients, response to chemotherapy was remarkable high and overall survival was significantly better compared to other subgroups including EGFR-mutated and ALK-fusion-positive NSCLC.
Derechos:	Tots els drets reservats.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Pulmons ; Càncer ; ROS1 ; Chemotherapy ; Lung cancer ; Non-small cell lung cancer ; Prognosis
Publicado en:	Oncotarget, Vol. 6 Núm. 12 (april 2015) , ISSN 1949-2553

DOI: 10.18632/oncotarget.3387
PMID: 25868855

9 p, 2.1 MB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Artículos > Artículos de investigación
Artículos > Artículos publicados